Pharmacological trials in irritable bowel syndrome (IBS) should include a run-in period of at least 2 weeks and dosing of…
Trending
- Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire)
- Century Health and Arizona Gastrointestinal Associates Partner to Accelerate Real-World Evidence in IBD and MASH (PR Newswire)
- EF-YOLO: A novel AI model for high-precision detection of colorectal polyps (EurekAlert)
- Who’s winning, losing the physician practice acquisition race? (Becker’s Healthcare)
- Clinician-Industry Collaboration: A Clinical Review of Ethical, Strategic, and Practical Considerations (GI & Endoscopy News)
- Wanna Be Startin’ Somethin’? Advice for Initiating a New Line of Service (GI & Endoscopy News)
- The robotic penguin that makes endoscopy optional (Technology.org)
- Peptides, Colonoscopy, and the Inversion of Risk (Medscape)
